Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Sarepta Therapeutics, Inc. SRPT

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
0.42
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — 1 — — 1 — — — — — —
Insider Ownership
4.73%

Capital & Financial Ratios

Market Cap
2,180.00
Revenue
1,974.34
Net Income
(136.72)
Free Cash Flow
74.97
Net Debt
59.13
Current Ratio
4.42
Debt/Equity
0.55
P/E ratio
0.00
P/S ratio
1.07
P/B ratio
1.39
Past 5Y EPS Growth
(1.21%)
This Y EPS Growth
146.29%
Next Y EPS Growth
(76.47%)
Next 5Y EPS Growth
5.64%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 1,676.25 1,354.79 939.65 788.49
Receivables 400.33 601.99 398.23 376.82
Inventory 322.86 749.96 914.74 904.27
Other 179.90 366.72 285.31 154.24
2,579.33 3,073.46 2,537.94 2,223.82
2023 2024 2025 Q'26
Payables 164.92 214.44 280.84 50.98
ST’ Debt 105.48 — — —
Other 17.85 13.47 11.39 16.56
653.66 731.68 1,095.29 502.91
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 730.80 401.25 — —
—
’25 744.86 611.09 399.36 442.93
2,198.24
’24 413.46 362.93 467.17 658.41
1,901.98
’23 253.50 261.24 331.82 396.78
1,243.34
’22 210.83 233.49 230.27 258.43
933.01
’21 146.93 164.09 189.41 201.46
701.89
’20 113.67 137.36 143.92 145.14
540.10
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (202.68) 197.07 — —
—
’25 (583.44) 261.34 (14.58) 131.21
(205.48)
’24 (242.08) 14.94 (70.70) 92.05
(205.79)
’23 (209.40) (122.23) (114.71) (54.66)
(500.99)
’22 (101.17) (66.81) (64.96) (92.39)
(325.35)
’21 (180.37) (109.15) (124.33) (29.33)
(443.17)
’20 627.79 (107.60) (238.19) (174.53)
107.47
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (205.76) 196.52 — —
—
’25 (629.33) 229.78 (43.26) 127.48
(315.33)
’24 (284.52) (14.22) (107.96) 53.96
(352.74)
’23 (218.97) (38.19) (155.48) (73.70)
(486.34)
’22 (106.73) (75.89) (74.42) (100.56)
(357.60)
’21 (201.52) (13.04) (133.57) (33.84)
(381.97)
’20 726.74 (126.77) (263.49) (203.14)
133.33
in millions of $

EPS

Mar Jun Sep Dec Year
’26 2.88 (0.05) — —
—
’25 (4.60) 1.89 (1.80) (3.93)
(7.13)
’24 0.37 0.07 0.34 1.50
2.34
’23 (5.86) (0.27) (0.46) 0.47
(5.80)
’22 (1.20) (2.65) (2.94) (1.24)
(8.03)
’21 (2.10) (1.02) (0.60) (1.42)
(5.15)
’20 (0.23) (1.93) (2.50) (2.40)
(7.11)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

2.8
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 61.28 55.25 91.34 10.42 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 134.08 159.89 173.25 129.84 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,162 1,314 1,372 835 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.80 0.95 1.39 2.63 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 933.01 1,243.34 1,901.98 2,198.24 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 85.00% 87.91% 83.22% 61.81% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (689.96) (520.10) 260.77 (702.22) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (73.95%) (41.83%) 13.71% (31.94%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (703.49) (535.98) 235.24 (713.41) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.21 (1.78) (2.55) 39.23 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.66 13.46 20.01 21.96 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (8.03) (5.80) 2.47 (7.13) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.72) (5.42) (2.16) (2.05) ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.37) 0.16 (1.55) (1.10) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.08) (5.26) (3.71) (3.15) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.40 9.30 16.07 11.39 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 87.56 92.40 95.08 100.12 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 49.63 0.00 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.72 7.15 6.08 0.98 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.40 10.34 7.57 1.89 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.25 6.80 6.01 0.97 ‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (29.18) (17.38) (32.41) (6.77) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (325.35) (500.99) (205.79) (205.48) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (32.25) 14.66 (146.96) (109.85) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (357.60) (486.34) (352.74) (315.33) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,938.26 1,925.67 2,341.78 1,442.65 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,559.29 1,238.00 1,137.12 828.97 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (430.08) (438.25) (217.67) (110.68) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 384.95 859.34 1,527.74 1,140.62 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (22.42%) (16.77%) 6.51% (19.51%) ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00% (39.75%) 10.40% (42.46%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (107.16%) (86.15%) 19.71% (53.47%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Sarepta Therapeutics (SRPT) exemplifies biotech volatility, with revenue exploding from $5.4 million in 2016 to $1.9 billion in 2024—driven by DMD therapies like Elevidys—while achieving its first profitability that year, flipping from deep losses to positive EPS and ROE. Revenue per employee soared 4,900%, gross margins stayed robust in the 80s-90s%, and a strong balance sheet with net cash provides R&D runway, signaling operational maturity after years of cash burn.

Yet, the outlook tempers enthusiasm: analysts project revenue peaking at $2.14 billion in 2025 before plunging 25% to $1.61 billion in 2026 amid potential competition, patent risks, and reimbursement hurdles. Insider selling continues without buys, and the stock—down sharply from 2024 highs—trades at compressed multiples like 6x PS, with analyst targets clustering near current levels despite profitability.

Is SRPT a discounted gem with DMD dominance potential, or a trap foreshadowed by revenue cliffs and pipeline risks? With key catalysts like Elevidys data and next-gen readouts ahead, the full analysis unpacks fundamentals, stock dynamics, and whether to buy the dip or trim.

Read full commentary →

Sarepta Therapeutics, Inc. (SRPT) Latest News

News by impact score

Fine-tune

15 Sep

4 www.marketbeat.com, 1:02 AM
Sarepta sees ELEVIDYS demand stabilizing while nearing FSHD and DM1 clinical readouts. Stabilizing ELEVIDYS demand plus pending FSHD and DM1 readouts mark major commercial and pipeline catalysts.

4 Sep

3 , 11:30 AM
Sarepta Therapeutics (SRPT) stock rose 37% since the prior earnings report on positive pipeline updates and market sentiment. Post-earnings stock gain signals improved sentiment with limited long-term structural change to operations.

27 Aug

4 stocktwits.com, 3:00 PM
Sarepta Therapeutics shares advance toward best weekly gain in five months ahead of late-2026 clinical data, with retail investors anticipating monumental comeback. Anticipation of late-2026 clinical data drives significant positive momentum and potential long-term trajectory shift for Sarepta.

24 Aug

3 , 10:18 AM
Regenxbio halted its gene therapy trial, triggering a sharp decline in the company's stock price. Competitor trial halt in gene therapy creates potential market opportunity for Sarepta.

12 Aug

3 transcript www.fool.com, 8:31 PM
Sarepta Therapeutics held its Q2 2026 earnings call covering quarterly financial results, operational updates, and forward outlook. Quarterly earnings calls typically deliver financial metrics and guidance that can shift near-term investor sentiment without altering long-term strategy.

6 Aug

4 , 2:05 PM
Sarepta Therapeutics beat Q2 earnings and sales estimates and updated its 2026 outlook. Beating estimates with an updated 2026 outlook signals strong performance that can materially shift valuation and sentiment.

4 transcript , 1:11 AM
Sarepta Therapeutics Inc reported strong profitability during its Q2 2026 earnings call. Strong profitability reported in Q2 2026 earnings call drives significant positive shift in company trajectory and investor sentiment.

3 , 1:59 PM
Sarepta Therapeutics faces competitive pressures despite pipeline updates, per RBC analysis. RBC flags competitive pressures that could moderately shift Sarepta's positioning and investor sentiment despite pipeline progress.

3 transcript www.marketbeat.com, 1:03 AM
Sarepta Therapeutics Q2 earnings call highlighted financial results, pipeline progress and operational updates for SRPT. Quarterly earnings data directly shapes near-term investor sentiment and valuation for SRPT.

5 Aug

4 , 4:05 PM
Sarepta Therapeutics reported second quarter 2026 financial results and recent corporate developments. Quarterly financial results directly affect investor sentiment and near-term stock performance for Sarepta.

3 transcript app.moby.co, 9:45 PM
Sarepta Therapeutics held its Q2 2026 earnings call covering quarterly financial results, product performance and pipeline updates. Quarterly earnings calls supply financial metrics and guidance that can move shares in the near term without fundamentally changing long-term company direction.

3 , 8:35 PM
Sarepta Therapeutics beat Q2 earnings and revenue estimates. Q2 beat indicates positive financial results that may lift near-term stock performance.

1 Aug

3 , 6:10 AM
Sarepta Therapeutics appointed a new CEO, raising questions on whether the stock is undervalued. New CEO appointment may shift strategy and investor views without guaranteed long-term trajectory change.

29 Jul

3 , 10:00 AM
Sarepta Therapeutics Q2 earnings expected to decline. Forecast of lower Q2 earnings can weigh on near-term investor sentiment and stock price.

27 Jul

4 , 8:30 AM
Sarepta Therapeutics appoints Michael Severino, M.D., as Chief Executive Officer. New CEO appointment at Sarepta Therapeutics represents a major leadership change likely to influence strategy and investor sentiment.

4 www.biopharmadive.com, 6:16 AM
Sarepta Therapeutics names ex-AbbVie executive Severino as CEO to lead turnaround efforts. CEO replacement with external pharma executive represents major leadership shift with potential to reshape strategy and investor views.

3 stocktwits.com, 12:33 PM
Morgan Stanley views Sarepta CEO transition as positive yet stays cautious on near-term SRPT stock performance. Sarepta CEO transition draws positive analyst note with near-term stock caution.

22 Jul

3 , 9:25 AM
SRPT stock declined 10% over the past week on investor concerns that Dyne Therapeutics may emerge as a competitive threat in genetic medicines. Mention of a rival raises moderate questions about SRPT's future market position without indicating immediate fundamental change.

21 Jul

3 stocktwits.com, 4:04 PM
SRPT stock dropped 4% after Citi flagged a potentially stronger rival in the Duchenne space. Citi note on stronger rival signals increased competition that may moderately affect SRPT positioning in Duchenne market.

20 Jul

4 , 1:31 PM
Sarepta shares fall after rival clears regulatory hurdle advancing Duchenne muscular dystrophy therapy. Rival progress directly threatens Sarepta's Duchenne market position and triggers stock decline.

13 Jul

4 , 9:10 PM
FDA accepts Sarepta Therapeutics sNDA, prompting analysis on whether SRPT remains undervalued after the regulatory step. FDA sNDA acceptance advances potential approval and revenue growth for Sarepta.

4 , 8:22 PM
FDA accepts sNDA for Sarepta Therapeutics DMD therapies, potentially altering the company's bull case and future market performance. FDA sNDA acceptance advances SRPT core DMD therapies toward approval and shifts company outlook.

30 Jun

4 stocktwits.com, 12:54 PM
Sarepta seeks permanent FDA approval for two Duchenne therapies, driving SRPT stock higher. Permanent FDA nods for core Duchenne therapies would markedly lift Sarepta's revenue and market position.

4 , 8:30 AM
Sarepta Therapeutics announced FDA acceptance of sNDAs for AMONDYS 45 and VYONDYS 53. FDA acceptance advances potential approvals and revenue for core Duchenne drugs.

18 Jun

3 , 11:04 AM
Sarepta's Elevidys shows signs of stabilization while its siRNA pipeline gains importance according to RBC. RBC notes on Elevidys stabilization and rising siRNA pipeline weight may moderately shift SRPT investor sentiment and outlook.

8 Jun

3 Zacks, 12:00 PM
Sarepta Therapeutics (SRPT) rating upgraded to Buy. Buy rating upgrade can lift short-term investor sentiment and trading activity for SRPT.

5 Jun

3 Insider Monkey, 8:18 PM
Sarepta Therapeutics Inc. shows improving profitability, positioning the company as one of the most shorted small-cap stocks to buy. Improving profitability at Sarepta Therapeutics Inc. supports positive investor sentiment and potential stock performance gains.

3 Zacks, 11:30 AM
Sarepta Therapeutics (SRPT) shares declined 19.9% since the last earnings report as investors reacted to the company's financial results and outlook. Post-earnings stock drop of this magnitude can pressure near-term valuation and sentiment but reflects standard quarterly updates rather than transformative shifts.

27 May

3 Insider Monkey, 5:19 PM
Sarepta Therapeutics maintains a solid cash position while outlining its priorities for 2026. Solid cash reserves combined with 2026 priority setting point to moderate influence on operational planning and investor views.

22 May

3 Zacks, 11:03 AM
Keros Therapeutics (KROS) released a stock guide on Rinvatercept development for Duchenne muscular dystrophy and amyotrophic lateral sclerosis with potential launch targeted for 2026. Rinvatercept progress signals emerging competition that may modestly pressure Sarepta's DMD market position by 2026.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us